Endeavor’s Phase IIb IPF study of taladegib meets endpoints

Phase 2positivetaladegibPositive

AI Analysis

Summary

Endeavor BioMedicines reported that its Phase IIb WHISTLE-PF trial of taladegib achieved primary and key secondary endpoints in idiopathic pulmonary fibrosis (IPF) patients.

Clinical Trial Data

Phase

IIb

Primary Endpoint

Met

Outcome Details

Primary and several key secondary endpoints met

Importance:7/10

Sentiment:

0.75

Phase IIbtaladegibIPFWHISTLE-PFpositive trial data

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on October 9, 2026 10:07 AM

Read Original